What is HC Wainwright’s Estimate for UTHR Q1 Earnings?

United Therapeutics Co. (NASDAQ:UTHR) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for United Therapeutics in a research report issued on Thursday, February 27th. HC Wainwright analyst A. Fein forecasts that the biotechnology company will post earnings of $7.07 per share for the quarter. HC Wainwright has a “Buy” rating and a $425.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q2 2025 earnings at $7.39 EPS, Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.89 EPS and FY2028 earnings at $37.60 EPS.

A number of other equities research analysts have also recently commented on UTHR. UBS Group upped their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $308.59 on Monday. The company has a 50-day simple moving average of $357.53 and a 200-day simple moving average of $360.79. United Therapeutics has a one year low of $221.53 and a one year high of $417.82. The stock has a market capitalization of $13.86 billion, a price-to-earnings ratio of 13.55, a PEG ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the previous year, the company earned $4.36 earnings per share.

Insider Transactions at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,164 shares of company stock worth $45,278,893 over the last ninety days. 11.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its position in United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after buying an additional 30 shares during the period. Parallel Advisors LLC grew its position in United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after buying an additional 30 shares during the period. Anchor Investment Management LLC grew its position in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after buying an additional 30 shares during the period. Great Lakes Advisors LLC grew its position in United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after buying an additional 31 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its position in United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.